Watchlist Price Alert

Grifols S.A. (GRFS)

NASDAQ: GRFS · Real-Time Price · USD

8.30

-0.06 (-0.72%)

At close: May 30, 2025, 3:59 PM

7.79

-6.13%

After-hours: May 30, 2025, 04:51 PM EDT

-0.72% (1D)

Bid	7.16
Market Cap	6.82B
Revenue (ttm)	7.36B
Net Income (ttm)	191.49M
EPS (ttm)	0.26
PE Ratio (ttm)	31.92
Forward PE	7.91
Analyst	n/a

Ask	8.42
Volume	291,003
Avg. Volume (20D)	1,011,766
Open	8.22
Previous Close	8.36
Day's Range	8.22 - 8.36
52-Week Range	5.79 - 9.96
Beta	0.93

About GRFS

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol GRFS

Website n/a

Full Company Profile

Why Price Moved

2 weeks ago

+8.87%

Grifols shares are trading higher after the compan... Unlock content with Pro Subscription

6 months ago

Grifols shares are trading lower after the company ended discussions with Brookfield Capital Partners regarding a potential acquisition.

News

2 days ago · businesswire.com

Mason Capital Management to Support Grifols Recommended Director Slate at Upcoming Ordinary General Meeting

NEW YORK--(BUSINESS WIRE)--Mason Capital Management LLC (“Mason”), a registered investment advisor to funds and accounts holding approximately 3% of Grifols S.A. (“Grifols” or the “Company”) (BME: GRF...

2 days ago · reuters.com

US court finds enough evidence to proceed with Grifols lawsuit against Gotham City

A New York court found enough evidence to continue with the defamation lawsuit filed by Spanish pharmaceutical company Grifols against short seller Gotham City Research, Grifols said in a statement on...

4 days ago · zacks.com

ADMA Biologics vs. Grifols: Which Plasma Therapy Stock Is the Better Buy?

At current levels, GRFS scores over ADMA with cheaper valuation, a broad portfolio, and strong EPS growth estimates despite the latter's robust Asceniv-driven momentum.

1 week ago · seekingalpha.com

Grifols: If This Works Out, It Has Massive Upside

Grifols offers compelling long-term upside, with potential returns exceeding 200% as the company recovers and grows earnings. Recent Q1 2025 results confirm strong operational recovery: top-line growt...

2 weeks ago · zacks.com

GRFS or NBIX: Which Is the Better Value Stock Right Now?

Investors interested in stocks from the Medical - Drugs sector have probably already heard of Grifols (GRFS) and Neurocrine Biosciences (NBIX). But which of these two stocks presents investors with th...

2 weeks ago · seekingalpha.com

Grifols, S.A. (GRFS) Q1 2025 Earnings Conference Call Transcript

Grifols, S.A. (NASDAQ:GRFS ) Q1 2025 Earnings Conference Call May 12, 2025 12:30 PM ET Company Participants Danny Segarra - VP, IR and Sustainability Nacho Abia - CEO Rahul Srinivasan - CFO Roland Wan...

2 weeks ago · reuters.com

Grifols says on course to meet 2025 outlook as net profit triples

Grifols's net profit almost tripled from a year earlier, which the Spanish drugmaker said reinforced its confidence in meeting its full-year guidance.

1 month ago · businesswire.com

IBL International collaborates with Grifols on advanced biomarker panels

MÄNNEDORF, Switzerland--(BUSINESS WIRE)--IBL International GmbH, a Tecan company, which develops, manufactures and offers specialty diagnostics, today announced a strategic partnership with Grifols, a...

2 months ago · reuters.com

Brookfield resumes Grifols takeover talks, El Confidencial reports

Canadian investment fund Brookfield has resumed talks on a potential takeover of Spanish pharmaceuticals company Grifols four months after a previous attempt fell through, news website El Confidencial...